Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Abstract 911: Butyrophilin 3A2 expression plays a critical role in phosphoantigen-mediated γδ T cell cytotoxicity of neuroblastoma cells

Andrew Ho, Hunter C. Jonus, Kelly C. Goldsmith

Cancer Res (2023) 83 (7_Supplement): 911.

https://doi.org/10.1158/1538-7445.AM2023-911

Published: 04 April 2023

View articletitled, Abstract 911: Butyrophilin 3A2 expression plays a critical role in phosphoantigen-mediated γδ T cell cytotoxicity of neuroblastoma cells

Journal Articles

Abstract 3545: The Yes-associated protein (YAP) regulates GD2 immunotherapy response in high-risk neuroblastoma

Adeiye A. Pilgrim, Hunter C. Jonus, Andrew Ho, Anna Cole, Jenny Shim, Kelly C. Goldsmith

Cancer Res (2023) 83 (7_Supplement): 3545.

https://doi.org/10.1158/1538-7445.AM2023-3545

Published: 04 April 2023

View articletitled, Abstract 3545: The Yes-associated protein (YAP) regulates GD2 immunotherapy response in high-risk neuroblastoma

Journal Articles

Abstract 4093: Dual targeted CAR immunotherapy for neuroblastoma using γδ T cells

Hunter C. Jonus, Jasmine Y. Lee, Jordan A. Silva, H. Trent Spencer, Kelly C. Goldsmith

Cancer Res (2023) 83 (7_Supplement): 4093.

https://doi.org/10.1158/1538-7445.AM2023-4093

Published: 04 April 2023

View articletitled, Abstract 4093: Dual targeted CAR immunotherapy for neuroblastoma using γδ T cells

Journal Articles

Abstract 3552: YAP-TEAD2 binding mediates therapy resistance in RAS-driven neuroblastoma

Jenny Shim, Andrew Ho, Hunter C. Jonus, Adeiye A. Pilgrim, Benjamin G. Barwick, Tracy T. Tang, Lawrence H. Boise, Kelly C. Goldsmith

Cancer Res (2023) 83 (7_Supplement): 3552.

https://doi.org/10.1158/1538-7445.AM2023-3552

Published: 04 April 2023

View articletitled, Abstract 3552: YAP-TEAD2 binding mediates therapy resistance in RAS-driven neuroblastoma

Journal Articles

Abstract 1547: Defining the optimal source of allogeneic γ δ T cells for novel cellular therapy approaches in neuroblastoma

Hunter Connell Jonus, Rebecca E. Burnham, Trent H. Spencer, Kelly C. Goldsmith

Cancer Res (2021) 81 (13_Supplement): 1547.

https://doi.org/10.1158/1538-7445.AM2021-1547

Published: 01 July 2021

View articletitled, Abstract 1547: Defining the optimal source of allogeneic γ δ T cells for novel cellular therapy approaches in neuroblastoma

Journal Articles

YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma

Jenny Shim, Jasmine Y. Lee, Hunter C. Jonus, Amanda Arnold, Robert W. Schnepp, Kaitlyn M. Janssen, Victor Maximov, Kelly C. Goldsmith

Cancer Res (2020) 80 (21): 4741–4753.

https://doi.org/10.1158/0008-5472.CAN-20-0025

Published: 03 November 2020

View articletitled, YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma

Includes: Supplementary data

Journal Articles

Abstract 2889: The Yes-Associated Protein plays a role in tumor formation, stemness, and therapy response in high risk neuroblastoma

Jenny Shim, Yoo Joo Lee, Kaitlyn Janssen, Alexa Fritz, Kelly C. Goldsmith

Cancer Res (2019) 79 (13_Supplement): 2889.

https://doi.org/10.1158/1538-7445.AM2019-2889

Published: 01 July 2019

View articletitled, Abstract 2889: The Yes-Associated Protein plays a role in tumor formation, stemness, and therapy response in high risk neuroblastoma

Journal Articles

Abstract B42: The properties of ex vivo expanded γδ T cells provide for the rational use of combination therapies

Jaquelyn T. Zoine, Kathryn S. Sutton, Kristopher A. Knight, Kelly C. Goldsmith, Christopher B. Doering, H. Trent Spencer

Cancer Res (2018) 78 (19_Supplement): B42.

https://doi.org/10.1158/1538-7445.PEDCA17-B42

Published: 01 October 2018

View articletitled, Abstract B42: The properties of ex vivo expanded γδ T cells provide for the rational use of combination therapies

Journal Articles

Abstract 3822: COUP-TF1 is a novel biomarker of therapy response in high-risk neuroblastoma.

Haneen Abdella, Srilatha Nalluri, Susan K. Peirce, Kelly C. Goldsmith

Cancer Res (2013) 73 (8_Supplement): 3822.

https://doi.org/10.1158/1538-7445.AM2013-3822

Published: 15 April 2013

View articletitled, Abstract 3822: COUP-TF1 is a novel biomarker of therapy response in high-risk neuroblastoma.

Journal Articles

Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma

Kelly C. Goldsmith, Michelle Gross, Susan Peirce, Dema Luyindula, Xueyuan Liu, Annette Vu, Michael Sliozberg, Rong Guo, Huaqing Zhao, C. Patrick Reynolds, Michael D. Hogarty

Cancer Res (2012) 72 (10): 2565–2577.

https://doi.org/10.1158/0008-5472.CAN-11-3603

Published: 14 May 2012

View articletitled, Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma

Includes: Supplementary data

Journal Articles

Abstract 5252: BH3 profiling identifies apoptosis resistance heterogeneity in neuroblastoma and predicts in vivo potency of Bcl2 antagonists

Kelly C. Goldsmith, Michelle Gross, Xueyuan Liu, Susan K. Peirce, Chengyu Prince, Michael D. Hogarty

Cancer Res (2010) 70 (8_Supplement): 5252.

https://doi.org/10.1158/1538-7445.AM10-5252

Published: 15 April 2010

View articletitled, Abstract 5252: BH3 profiling identifies apoptosis resistance heterogeneity in neuroblastoma and predicts in vivo potency of Bcl2 antagonists

Journal Articles

Modified BH3-domain peptides effectively activate apoptosis in neuroblastoma-derived cell lines in vitro

Kelly C. Goldsmith, Xueyuan Liu, Vincent Dam, Brian Morgan, Michael D. Hogarty

Cancer Res (2004) 64 (7_Supplement): 1286.

Published: 01 April 2004

View articletitled, Modified BH3-domain peptides effectively activate apoptosis in neuroblastoma-derived cell lines in vitro

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 911: Butyrophilin 3A2 expression plays a critical role in phosphoantigen-mediated γδ T cell cytotoxicity of neuroblastoma cells

Abstract 3545: The Yes-associated protein (YAP) regulates GD2 immunotherapy response in high-risk neuroblastoma

Abstract 4093: Dual targeted CAR immunotherapy for neuroblastoma using γδ T cells

Abstract 3552: YAP-TEAD2 binding mediates therapy resistance in RAS-driven neuroblastoma

Abstract 1547: Defining the optimal source of allogeneic γ δ T cells for novel cellular therapy approaches in neuroblastoma

YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma

Abstract 2889: The Yes-Associated Protein plays a role in tumor formation, stemness, and therapy response in high risk neuroblastoma

Abstract B42: The properties of ex vivo expanded γδ T cells provide for the rational use of combination therapies

Abstract 3822: COUP-TF1 is a novel biomarker of therapy response in high-risk neuroblastoma.

Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma

Abstract 5252: BH3 profiling identifies apoptosis resistance heterogeneity in neuroblastoma and predicts in vivo potency of Bcl2 antagonists

Modified BH3-domain peptides effectively activate apoptosis in neuroblastoma-derived cell lines in vitro

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only